An update on disease biomarkers for Hodgkin lymphoma

References

• Sasse S, Brockelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35:1999–2007.
   PubMed Web of Science ®Google Scholar
• Skoetz N, Will A, Monsef I, et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;5:Cd007941.
   PubMed Web of Science ®Google Scholar
• Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:Cd009411.
   PubMedGoogle Scholar
• Borchmann S, Muller H, Haverkamp H, et al. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). Leukemia. 2019;33:439–446.
   PubMed Web of Science ®Google Scholar
• Franklin J, Eichenauer DA, Becker I, et al. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev. 2017;9:Cd008814.
   PubMedGoogle Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161:76–86.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;2189–2192. DOI:10.1182/blood-2015-11-681064
   PubMedGoogle Scholar
• Sasse S, Reddemann K, Diepstra A, et al. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. Haematologica. 2019;104:e21–e24.
   PubMed Web of Science ®Google Scholar
• Hude I, Sasse S, Brockelmann PJ, et al. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition. Br J Haematol. 2018;181:837–840.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160–1168.
   PubMed Web of Science ®Google Scholar
• Aldin A, Trivella M, Estcourt LJ, et al. P026 (0057) interim- pet results for prognosis in adults with hodgkin lymphoma: a prognostic factor exemplar review (Preliminary results). HemaSphere. 2018;2:12.
   Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Jung S-H, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132:1013–1021.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–2429.
   PubMed Web of Science ®Google Scholar
• Press OW, Li H, Schöder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: southwest oncology group S0816. J clin oncol. 2016;34:2020–2027.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Gioia DM, et al. Interim positron emission tomography response–adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J clin oncol. 2016;34:1376–1385.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790–2802.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–1661.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456–1463.
   PubMed Web of Science ®Google Scholar
• Chung J-S, Song M-G, Kim D-Y, et al. P025 (0033) metabolic tumor volume by positron emission tomography/computed tomography for deciding the therapeutic modality in patients with early stage Hodgkin’s lymphoma. HemaSphere. 2018;2:12.
   Google Scholar
• Mettler J, Muller H, Voltin CA, et al. Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. 2019;60(2):207–211.
   Google Scholar
• Prochazka V, Gawande RS, Cayci Z, et al. Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2018;24:64–70.
   PubMed Web of Science ®Google Scholar
• Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:6812–6819.
   PubMed Web of Science ®Google Scholar
• Jones K, Vari F, Keane C, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:731–742.
   PubMed Web of Science ®Google Scholar
• Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013;88(2):113–115.
   Web of Science ®Google Scholar
• Lake A, Nixon I, Beattie P, et al. P031 (0145) evaluation of CCL17 (TARC) as a diagnostic biomarker for classical Hodgkin lymphoma: interim results from the candel study. HemaSphere. 2018;2:14–15.
   Google Scholar
• Guidetti A, Mazzocchi A, Miceli R, et al. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin lymphoma. Leuk Res. 2017;62:91–97.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762–1765.
   Web of Science ®Google Scholar
• Farina L, Rezzonico F, Spina F, et al. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:1982–1988.
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Hsu AK, Neeson P, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55:1053–1060.
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Alsada ZND, van Imhoff GW, et al. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175:868–875.
   PubMed Web of Science ®Google Scholar
• Bräuninger A, Desch AK, Kunze K, et al. T008 (0050) genotyping circulating tumor Dna of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy. HemaSphere. 2018;2:4.
   Google Scholar
• Cuccaro A, Annunziata S, Cupelli E, et al. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Med. 2016;5:398–406.
   PubMed Web of Science ®Google Scholar
• Cirillo M, Reinke S, Klapper W, et al. The translational science of hodgkin lymphoma. Br J Haematol. 2019;184:30–44.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 2016;380:243–252.
   PubMed Web of Science ®Google Scholar
• Engert A, Younes A. Hodgkin lymphoma: a comprehensive overview. 2nd ed. Heidelberg: Springer; 2015.
   Google Scholar
• Venkataraman G, Mirza MK, Eichenauer DA, et al. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014;165:287–299.
   PubMed Web of Science ®Google Scholar
• Mestre F, Gutierrez A, Ramos R, et al. Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood. 2012;119:6072–6079.
   PubMed Web of Science ®Google Scholar
• Ouyang J, Plutschow A, Pogge von Strandmann E, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood. 2013;121:3431–3433.
   PubMed Web of Science ®Google Scholar
• Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011;117:6638–6649.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J clin oncol. 2016;34:2690–2697.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J clin oncol. 2013;31:256–262.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Borchmann S, Engert A. The genetics of Hodgkin lymphoma: an overview and clinical implications. Curr Opin Oncol. 2017;29:307–314.
   PubMed Web of Science ®Google Scholar
• Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J clin oncol. 2013;31:692–700.
   PubMed Web of Science ®Google Scholar
• Chan FC, Mottok A, Gerrie AS, et al. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. J clin oncol. 2017;35:3722–3733.
   PubMed Web of Science ®Google Scholar
• Liang WS, Vergilio JA, Salhia B, et al. Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. Oncologist. 2019;24:219–228.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Doring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012;120:4609–4620.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131:2454–2465.
   PubMed Web of Science ®Google Scholar
• Navarro A, Munoz C, Gaya A, et al. MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients. PLoS One. 2013;8:e64716.
   PubMed Web of Science ®Google Scholar
• Navarro A, Diaz T, Martinez A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–2951.
   PubMed Web of Science ®Google Scholar
• Lupo J, Germi R, Lancar R, et al. Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern cART era. Aids. 2019. DOI:10.1097/QAD.0000000000002129
   PubMed Web of Science ®Google Scholar
• Ul-Haq I, Dalla Pria A, Suardi E, et al. Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. Med Oncol. 2018;35:53.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin’s Lymphoma. Clin Cancer Res. 2006;12:460–464.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121:3547–3553.
   PubMed Web of Science ®Google Scholar
• Spacek M, Hubacek P, Markova J, et al. Plasma EBV-DNA monitoring in Epstein–Barr virus-positive Hodgkin lymphoma patients. APMIS. 2011;119:10–16.
   PubMed Web of Science ®Google Scholar
• Park JH, Yoon DH, Kim S, et al. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Ann Hematol. 2016;95:801–808.
   PubMed Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. Blood. 2018. DOI:10.1182/blood-2017-11-812073
   Web of Science ®Google Scholar
• Primerano S, Burnelli R, Carraro E, et al. Kinetics of circulating plasma cell-free DNA in paediatric classical Hodgkin lymphoma. J Cancer. 2016;7:364–366.
   PubMed Web of Science ®Google Scholar
• Bessi L, Viailly P-J, Bohers E, et al. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60:498–502.
   PubMed Web of Science ®Google Scholar
• Camus V, Stamatoullas A, Mareschal S, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica. 2016;101:1094–1101.
   PubMed Web of Science ®Google Scholar
• van Eijndhoven MA, Zijlstra JM, Groenewegen NJ, et al. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight. 2016;1:e89631.
   PubMed Web of Science ®Google Scholar
• Drees EEE, Eijndhoven M, Ciocanea-Teodorescu I, et al. T010 (0113) clinical validation of an extracellular vesicle associated mirna detection assay to monitor therapy response in classical Hodgkin lymphoma patients. HemaSphere. 2018;2:5.
   Google Scholar
• Wylie B, Macri C, Mintern JD, et al. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers (Basel). 2019;11. DOI:10.3390/cancers11040521
   Web of Science ®Google Scholar
• Galati D, Zanotta S, Corazzelli G, et al. Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma. Br J Haematol. 2019;184:594–604.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Moccia AA, Donaldson J, Chhanabhai M, et al. International prognostic score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30:3383–3388.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Kostakoglu L, Zaucha JM, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J clin oncol. 2014;32:2705–2711.
   PubMed Web of Science ®Google Scholar
• Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin North Am. 2014;28:87–103.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the lugano classification. J clin oncol. 2014;32:3059–3067.
   PubMed Web of Science ®Google Scholar